NEW YORK, Oct. 12 (GenomeWeb News) - Cellzome and Graffinity, a unit of Santhera Pharmaceuticals, will receive €1.1 million ($1.3 million) each from the German Ministry of Research and Education to discover new treatments for immune system disorders, the Heidelberg, Germany-based companies said today.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.